KKR-owned Healthium, Temasek-backed Romsons in race to buy 70-80% stake in BL Lifesciences
The company is likely to be valued ₹1,800-2,000 crore, the people said. KPMG is advising the promoters on the stake sale. BL Lifesciences, a fourth-generation family-owned business, primarily focuses on products for cardiac surgery, critical care, interventional cardiology, anaesthesia and surgical care.
Mumbai: KKR-backed Healthium Medtech and Temasek-aligned Romsons Group are the leading contenders in a bid to secure a 70-80% stake in BL Lifesciences, a prominent medical devices manufacturer and distributor based in Delhi. The company is expected to be valued between ₹1,800-2,000 crore, according to sources familiar with the situation.
KPMG is currently representing the company's promoters in the stake sale process. BL Lifesciences, a fourth-generation family-owned enterprise, specializes in various products catering to cardiac surgery, critical care, interventional cardiology, anesthesia, and surgical care. Their product range includes perfusion systems, cath-lab kits, central venous catheters, invasive pressure-monitoring systems, and an extensive selection of surgical consumables such as blood bags, instruments, and wound-care products.
Representatives from KKR and Temasek did not provide any comment on the matter. An attempt to reach BL Lifesciences' managing director, Sunil Aggarwal, via email also went unanswered as of the latest update.
Written by urgent.news from ETHealthworld's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.